- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05311423
The Prevalence and Reproductive Outcome of Infertile Women With Genital Tuberculosis (TB-PRIME)
The Prevalence of Genital Tuberculosis and the Impact on Reproductive Outcomes in Infertile Women: a National Multicenter Prospective Cohort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project aims to recruit infertile female with high risk of tuberculosis infecton who need assisted reproductive treatment in multiple reproductive centers. The infertility-related medical history and laboratory examination results were recorded according to clinical routine, and other essential information such as tuberculosis symptoms, tuberculosis-related history and other health conditions were also recorded, and the pregnancy outcomes of these patients were followed up.
According to the results of clinical screening, they were divided into four cohorts: non-tuberculosis (non-TB) group, latent tuberculosis infection (LTBI) group, subclinical genital tuberculosis infection (SGTB) group and female genital tuberculosis infection (FGTB) group.
Non-TB group: QuantiFERON-TB test (QFT) negative, continue assisted reproductive treatment; LTBI group: QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, acid-fast bacilli (AFB) microscopy, Mycobacterium tuberculosis (Mtb) culture, or GeneXpert MTB/RIF Ultra test results. Then assisted reproductive treatment can be continued, but follow-up for tuberculosis-related symptoms is required; SGTB group: QFT positive. Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, AFB microscopy, Mtb culture, but GeneXpert MTB/RIF Ultra positive test results. They are recommended to receive 6-month first-line standard anti-tuberculosis treatment (ATT) regimen; FGTB group: QFT positive. Excluded active pulmonary tuberculosis, regardless of GeneXpert MTB/RIF Ultra results, at least one of these test results, including endometrial histopathologiy, AFB microscopy, Mtb culture is positive, they will receive 6-month ATT.
Patients diagnosed with SGTB and FGTB will receive 6-month first-line standard ATT before ART, and follow up their anti-tuberculosis drug-related adverse reactions (TB-ARs) according to clinical routine to prevent the occurrence of grade 3-4 adverse drug reactions.
All cohorts will be followed up for pregnancy outcomes after entering the assisted reproduction cycle, and the pregnancy outcomes of all subjects after the first assisted reproduction after enrollment were recorded. Follow-up nodes included the 2nd, 4th, 10th weeks and 37th weeks of gestation. Follow-up content includes pregnancy status. Follow-up subjects will be terminated when adverse pregnancy outcomes such as ectopic pregnancy and miscarriage occurred; follow-up of pregnant participants will be extended to 2 weeks postpartum. Participants from the SGTB or FGTB group achieve pregnant naturally after drug withdrawal, the follow-up of the natural pregnancy outcome will be started as well.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200051
- Recruiting
- Shanghai first maternity and infant hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 1) Female, aged ≥20 years and <43 years old;
- 2) In line with conventional assisted reproduction indications;
3) Meet any of the following:
- with tuberculosis infection history;
- with a history of close contact to tuberculosis patients;
- exact positive IGRA results in the past or chest imaging indicated a past history of pulmonary tuberculosis;
- suspected symptoms of tuberculosis, including fever, night sweats, fatigue, cough and sputum;
- suspected symptoms of genital tuberculosis, including lower abdominal pain, abnormal menstruation, fallopian tube stenosis, obstruction, thickening, beading changes, uterine cavity adhesions, deformation, pelvic adhesions, etc.;
- 4) Voluntarily join the study and sign the informed consent
Exclusion Criteria:
- 1) Co-infection with HIV;
- 2) Chromosomal abnormalities;
- 3) suspected genital tuberculosis infection symptoms (participants meet inclusion criteria 3)e in Inclusion Criteria) known to be caused only by factors part from tuberculosis, such as endocrine factors, history of ectopic pregnancy, history of uterine curettage, chronic pelvic inflammatory disease, endometriosis, malignant tumors, etc.;
- 4) There are other serious physical or mental illnesses that are not suitable for selection;
- 5) Participate in other clinical studies that would affect this study at the same time.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Non-TB Group
QuantiFERON-TB test (QFT) negative, continue assisted reproductive treatment
|
Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden.
A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy.
Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB.
For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
|
Latent tuberculosis infection Group
QFT positive.
Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, acid-fast bacilli (AFB) microscopy, Mycobacterium tuberculosis (Mtb) culture, or GeneXpert MTB/RIF Ultra test results.
Then assisted reproductive treatment can be continued, but follow-up for tuberculosis-related symptoms is required
|
Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden.
A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy.
Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB.
For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
|
Subclinical genital tuberculosis Group
QFT positive.
Excluded active pulmonary tuberculosis, patients have negative endometrial histopathology, AFB microscopy, Mtb culture, but GeneXpert MTB/RIF Ultra positive test results.
They are recommended to receive 6-month first-line standard anti-tuberculosis treatment (ATT) regimen
|
Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden.
A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy.
Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB.
For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
|
Female genital tuberculosis Group
QFT positive.
Excluded active pulmonary tuberculosis, regardless of GeneXpert MTB/RIF Ultra results, at least one of these test results, including endometrial histopathologiy, AFB microscopy, Mtb culture is positive, they will receive 6-month ATT
|
Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden.
A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy.
Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB.
For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical pregnancy rate of ART
Time Frame: 2 years
|
the number of participants with gestational sacs seen by ultrasound examination 4-6 weeks after transplantation/the number of embryo transfer cycles in this group
|
2 years
|
Continued pregnancy rate of ART
Time Frame: 2 years
|
the number of patients whose pregnancy was confirmed by repeat ultrasonography at 10th week of gestation/the number of embryo transfer cycles in this group
|
2 years
|
Prevalence of SGTB among infertile women
Time Frame: 6 months
|
the number of SGTB participants/the total number of this project
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of FGTB/LTBI among infertile women
Time Frame: 2 years
|
the number of each group/the total number of this project
|
2 years
|
Abortion rate
Time Frame: 2 years
|
number of abortions/number of clinical pregnancy in non-TB or LTBI or SGTB or FGTB group
|
2 years
|
Ectopic pregnancy rate
Time Frame: 2 years
|
number of ectopic pregnancy/number of clinical pregnancy in non-TB or LTBI or SGTB or FGTB group
|
2 years
|
Preterm birth rate
Time Frame: 2 years
|
the number of premature births/the number of clinical pregnancy in non-TB or LTBI or SGTB or FGTB group
|
2 years
|
Live birth rate
Time Frame: 2 years
|
the number of live births/the number of clinical pregnancy in non-TB or LTBI or SGTB or FGTB group
|
2 years
|
Maternal mortality rate
Time Frame: 2 years
|
the number of maternal mortality/the number of clinical pregnancy in non-TB or LTBI or SGTB or FGTB group
|
2 years
|
Neonatal mortality rate
Time Frame: 2 years
|
the number of neonatal mortality/the number of clinical pregnancy in non-TB or LTBI or SGTB or FGTB group
|
2 years
|
Spontaneous pregnancy rate
Time Frame: 2 years
|
number of Spontaneous pregnancy/number of subjects completed ATT in FGTB/SGTB group
|
2 years
|
The incidence of grade 3-4 adverse events
Time Frame: 2 years
|
the number of patients with grade 3-4 adverse events during anti-tuberculosis treatment / the total number of in FGTB/SGTB group
|
2 years
|
The rate of drug discontinuation due to adverse drug reactions
Time Frame: 2 years
|
the number of patients who discontinued in anti-tuberculosis treatment due to adverse drug reactions / the total number of patients with adverse reactions in FGTB/SGTB group
|
2 years
|
Treatment completion rate
Time Frame: 2 years
|
number of patients who completed anti-tuberculosis treatment / total number of patients in this group × 100%
|
2 years
|
Incidence of active tuberculosis of LTBI group during 1 year after enrollment
Time Frame: 1 year
|
the number of subjects who develop to active tuberculosis during 1 year after enrollment/the number of subjects of LTBI group
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2021-840
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility, Female
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Newlife Fertility CentreRecruitingInfertility | Infertility,Female | Infertility Unexplained | Infertility of Uterine Origin | Infertility; Female, NonimplantationCanada
-
Cairo UniversityCompleted
-
Navy General Hospital, BeijingUnknownFemale Infertility Due to Nonimplantation of OvumChina
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
Sapientiae InstituteTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Woman's Health University Hospital, EgyptCompletedFemale Infertility Due to Diminished Ovarian ReserveEgypt
Clinical Trials on QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra
-
University College, LondonActive, not recruitingHIV | Latent TuberculosisUnited Kingdom